Barbara Yanni
Director/Board Member bei TREVENA, INC.
Vermögen: 131 558 $ am 31.03.2024
Aktive Positionen von Barbara Yanni
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TREVENA, INC. | Director/Board Member | 01.07.2014 | - |
Independent Dir/Board Member | 01.07.2014 | - | |
VACCINEXPAR | Director/Board Member | 01.02.2015 | - |
Independent Dir/Board Member | 01.02.2015 | - | |
PHARMING GROUP N.V. | Director/Board Member | 11.12.2020 | - |
Mesentech, Inc.
Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | Director/Board Member | 01.11.2020 | - |
Independent Dir/Board Member | 01.11.2020 | - |
Karriereverlauf von Barbara Yanni
Ehemalige bekannte Positionen von Barbara Yanni
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ONCORUS, INC. | Director/Board Member | 27.07.2021 | 27.07.2023 |
Independent Dir/Board Member | 27.07.2021 | 27.07.2023 | |
AKCEA THERAPEUTICS, INC. | Director/Board Member | 13.12.2019 | 12.10.2020 |
Independent Dir/Board Member | 13.12.2019 | 12.10.2020 | |
ABIONYX PHARMA | Director/Board Member | 31.07.2018 | 01.01.2020 |
Independent Dir/Board Member | 31.07.2018 | 01.01.2020 | |
Symic Bio, Inc.
Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA. | Director/Board Member | 23.02.2015 | 01.08.2019 |
Symic Holdings LLC
Symic Holdings LLC BiotechnologyHealth Technology Symic Holdings LLC develops new category of therapeutics. The company was founded by John Paderi, Kate Stuart and Alyssa Panitch and is headquartered in Emeryville, CA. | Director/Board Member | 01.01.2015 | 01.01.2019 |
░░░░░ ░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Barbara Yanni
New York University | Graduate Degree |
Wellesley College | Undergraduate Degree |
Stanford Law School | Graduate Degree |
Statistik
International
Vereinigte Staaten | 11 |
Niederlande | 2 |
Frankreich | 2 |
Operativ
Director/Board Member | 9 |
Independent Dir/Board Member | 6 |
Graduate Degree | 2 |
Sektoral
Health Technology | 11 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 6 |
---|---|
MERCK & CO., INC. | Health Technology |
VACCINEXPAR | Health Technology |
PHARMING GROUP N.V. | Health Technology |
ABIONYX PHARMA | Health Technology |
TREVENA, INC. | Health Technology |
ONCORUS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Symic Bio, Inc.
Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA. | Health Technology |
Symic Holdings LLC
Symic Holdings LLC BiotechnologyHealth Technology Symic Holdings LLC develops new category of therapeutics. The company was founded by John Paderi, Kate Stuart and Alyssa Panitch and is headquartered in Emeryville, CA. | Health Technology |
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Mesentech, Inc.
Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | Health Technology |
- Börse
- Insiders
- Barbara Yanni
- Erfahrung